Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson’s disease

References

• RascolOGoetzCKollerWTreatment interventions for Parkinson’s disease:an evidence based assessmentLancet20022591589159812047983
   PubMed Web of Science ®Google Scholar
• RajputAHUittiRJRajputAHOfferKPTimely levodopa (LD) administration prolongs survival in Parkinson’s diseaseParksinsonism Relat Dis19972159165
   Google Scholar
• AntoniniAAbbruzzeseGBaronePCOMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): Relevance for motor and nonmotor featuresNeuropsychiatr Dis Treat200821918728767
   PubMedGoogle Scholar
• Van LaarTLevodopa-induced response fluctuations in patients with Parkinson’s disease:strategies for managementCNS Drugs20032747548912751918
   PubMed Web of Science ®Google Scholar
• OlanowCWWattsRLKollerWCAn algorithm (decision tree) for the management of PD;2001:treatment guidelinesNeurology200156suppl 5S1S8811402154
   PubMed Web of Science ®Google Scholar
• Leegwater-KimJWatersCRole of tolcapone in the treatment of Parkinson’s diseaseExp Rev Neurother2007216491657
   Google Scholar
• KaakkolaSClinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s diseaseDrugs2000291233125010882160
   PubMed Web of Science ®Google Scholar
• NapolitanoADel DottoPPetrozziLPharmacokinetics and pharmacodynamics of l-dopa after acute and 6-week tolcapone administration in patients with Parkinson’s diseaseClin Neuropharmacol199922242910047930
   PubMed Web of Science ®Google Scholar
• CeravoloRPicciniPBaileyDL18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson’s diseaseSynapse20022320120711793426
   PubMed Web of Science ®Google Scholar
• DingemanseJJorgaKMSchmittMIntegrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration t humansClin Pharmacol Ther1995a575085177768073
   PubMed Web of Science ®Google Scholar
• DingemanseJJorgaKMZurcherGPharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopaBr J Clin Pharmacol1995b402532628527287
   PubMed Web of Science ®Google Scholar
• JorgaKSedekGFottelerBOptimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderlyClin Pharmacol Ther1997223003109333106
   PubMed Web of Science ®Google Scholar
• Valeant Pharmaceuticals International. Prescribing information: Tasmar® (tolcapone) tablets [online]. Available from URL:http://www.Tasmar.com
   Google Scholar
• JorgaKFottelerBBankenLPopulation pharmacokinetics of tolcapone in Parkinson’s patients in dose finding studiesBr J Clin Pharmacol200029394810606836
   PubMed Web of Science ®Google Scholar
• JorgaKFottelerBSedekGThe effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulationJ Neurol19982452232309591224
   PubMed Web of Science ®Google Scholar
• JorgaKFottelerBSedekGThe effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulationJ Neurol19992452232309591224
   PubMed Web of Science ®Google Scholar
• KeatingGMLyseng-WilliamsonKATolcapone. A review of its use in the management of Parkinson’s diseaseCNS Drugs20052916518415697329
   PubMed Web of Science ®Google Scholar
• BonifacioMJPalmaPNAlmeidaLSoares-da-SilvaPCatechol-O-methyltransferase and its inhibitors in Parkinson’s diseaseCNS Drug Rev20072335237917894650
   PubMedGoogle Scholar
• AlmeidaLSoares-da-SilvaPPharmacokinetic and pharmacodynamic profiles of BIA-3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjectsJ Clin Pharmacol2003231350236014615471
   PubMed Web of Science ®Google Scholar
• FactorSAMolhoESFeustelPJLong-term comparative experience with tolcapone and entacapone in advanced Parkinson’s diseaseClin Neuropharmacol20012429529911586115
   PubMed Web of Science ®Google Scholar
• LimousinPPollakPPfefenJPAcute administration of levodopabeserazide and tolcapone, a COMT inhibitor, in Parkinson’s diseaseClin Neuropharmacol199528358265
   Google Scholar
• OlanowCWObesoJAPreventing levodopa-induced dysknesiasAnn Neurol200027S167S17610762145
   PubMed Web of Science ®Google Scholar
• OlanowCWTolcapone and hepatotoxic effects. Tasmar Advisory PanelArch Neurol20005726326710681087
   PubMed Web of Science ®Google Scholar
• MullerTKuhnWTolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson’s disease patintsEur J Clin Pharmacol20062244745016758261
   PubMed Web of Science ®Google Scholar
• Leegwater-KimJWatersCTolcapone in the management of Parkinson’s diseaseExpert Opin Pharmacother200622263227017059382
   PubMed Web of Science ®Google Scholar
• SuchowerskyOBaileyPPourcherEComparison of two doses of tolcapone added to levodopa in nonfluctuating patients with PDClin Neuropharmacol20012421422011479392
   PubMed Web of Science ®Google Scholar
• OlanowCWWatkinsPBTolcapone: an efficacy and safety reviewClin Neuropharmacol20073028729417909307
   PubMed Web of Science ®Google Scholar
• OlanowCWTolcapone and hepatotoxic effects. Tasmar Advisory PanelArch Neurol20002726326710681087
   PubMedGoogle Scholar
• LeesAJRatziuVTolosaESafety and tolerability of adjunctive tolcapone therapy in early Parkinson’s disease patientsJ Neurol Neurosurg Psychiatry20072894494817098835
   PubMed Web of Science ®Google Scholar
• BorgesNTolcapone in Parkinson’s disease:liver toxicity and clinical efficacyExpert Opin Drug Saf20052697315709899
   PubMedGoogle Scholar
• RojoAFontanAMenaMATolcapone increases plasma catecholamine levels in patients with Parkinson’s diseaseParkinsonism Relat Disord20012939611248589
   PubMed Web of Science ®Google Scholar
• European Medicines Evaluation Agency. Tasmar: summary of product characteristics [online]. Available from URL:http://www.emea.eu.int
   Google Scholar
• DavisTLRoznoskiMBurnsRSEffects of tolcapone in Parkinson’s patients taking l-dihydroxyphenylalanine/carbidopa and selegilineMov Disord1995203493517651456
   PubMed Web of Science ®Google Scholar
• RajputAHMartinWSaint-HilaireMHTolcapone improves motor function in parkinsonian patients with the “wearing off” phenomenon a double-blind, placebo-controlled, multi-center trialNeurology199729106610719339691
   PubMed Web of Science ®Google Scholar
• KurthMCAdlerCHHilaireMSthe Tolcapone Fluctuator Study Group ITolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations:a multicenter, double-blind, randomized, placebo-controlled trialNeurology19972881879008498
   PubMed Web of Science ®Google Scholar
• BaasHBeiskeAGGhikaJCatechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patientsJ Neurol Neurosurg Psychiatry1997234214289343116
   PubMed Web of Science ®Google Scholar
• AdlerCHSingerCO’BrienCthe Tolcapone Fluctuator Study Group IIIRandomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopacarbidopaArch Neurol199825108910959708959
   PubMedGoogle Scholar
• DupontEBurgunderJMFindleyLJTolcapone added to levodopa in table parkinsonian patients:a double-blind placebo-controlled study. Tolcapone in Parkinson’s Disease Study Group II (TIPS II)Mov Disord1997229289349399217
   PubMed Web of Science ®Google Scholar
• WatersCHKurthMBaileyPthe Tolcapone Stable Study GroupTolcapone in stable Parkinon’s disease:efficacy and safety of long-term treatmentNeurology1997296656719305320
   PubMed Web of Science ®Google Scholar
• GaspariniMFabrizioEBonifatiVCognitive improvement during tolcapone treatment in Parkinson’s diseaseJ Neural Transm19972048878949451720
   PubMed Web of Science ®Google Scholar
• OnofrjMThomasAIaconoDSwitch-over from tolcapone to entacapone in severe Parkinson’s disease patientsEuro Neurol2001261116
   Web of Science ®Google Scholar
• ColosimoCThe rise and fall of tolcaponeJ Neurol199924688088210552233
   PubMed Web of Science ®Google Scholar
• HalkiasIAHaqIHuangZWhen should levodopa therapy be initiated patients with Parkinson’s disease?Drugs Aging2007246173
   Web of Science ®Google Scholar
• HauserRAMcDermottMPMessingSFactors associated with the development of motor fluctuations and dyskinesias in Parkinson diseaseArch Neurol2006231756176017172616
   PubMedGoogle Scholar
• LeesAJAlternatives to levodopa in the initial treatment of early Parkinson’s diseaseDrugs Aging20052273174016156677
   PubMed Web of Science ®Google Scholar
• MullerTWerneBFowlerBKuhnWNigral endothelial dysfunction, homocysteine, and Parkinson’s disease [letter]Lancet199925412612710408491
   PubMed Web of Science ®Google Scholar
• MullerTWoitallaDKuhnWBenefit of folic acid supplementation in parkinsonian patients treated with levodopaJ Neurol Neurosurg Psychiatry20032454912640094
   PubMed Web of Science ®Google Scholar
• PahwaRFactorSALyonsKEPractice parameter:treatment of Parkinson’s disease with motor fluctuations and dyskinesia (an evidence-based review):report of the quality standards subcommittee of the American Academy of NeurologyNeurology20062698398516606909
   PubMed Web of Science ®Google Scholar
• SarniiANuttJGRansomBRParkinson’s diseaseLancet200426317831793
   Google Scholar
• The Entacapone to Tolcapone Switch Study InvestigatorsEntacapone to tolcapone switch:multicenter double-blind, randomized, active controlled trial in advanced Parkinson’s diseaseMov Disord2007141917089403
   PubMed Web of Science ®Google Scholar